<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Active drugs by class in multiple myeloma</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Active drugs by class in multiple myeloma</h1>
<div class="graphic"><div class="figure"><div class="ttl">Active drugs by class in multiple myeloma</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="50%"></colgroup> <tbody> <tr> <td class="subtitle1">Drug class</td> <td class="subtitle1">Considerations</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Immunomodulatory drugs</td> </tr> <tr> <td class="indent1"> <ul> <li>Lenalidomide</li> <li>Pomalidomide</li> <li>Thalidomide</li> </ul> </td> <td> <ul> <li>Antithrombotic prophylaxis</li> <li>Dose adjustments for renal dysfunction</li> <li>May impair stem cell mobilization</li> <li>Increased risk of second primary malignancies</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="2">Proteasome inhibitors</td> </tr> <tr> <td class="indent1"> <ul> <li>Bortezomib</li> <li>Carfilzomib</li> <li>Ixazomib</li> </ul> </td> <td> <ul> <li>Increased risk of herpes zoster and infections related to neutropenia</li> <li>Risk of peripheral neuropathy varies with agent</li> <li>Dose adjustments for hepatic dysfunction</li> <li>Rare cases of reversible posterior leukoencephalopathy syndrome</li> <li>Heart failure and hypertension</li> <li>Acute renal failure with carfilzomib</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="2">Monoclonal antibodies<sup>*</sup></td> </tr> <tr> <td class="indent1"> <ul> <li>Daratumumab</li> <li>Isatuximab</li> <li>Elotuzumab</li> </ul> </td> <td> <ul> <li>Acute and delayed infusion reactions</li> <li>Daratumumab, isatuximab, and elotuzumab associated with increased risk of herpes zoster and opportunistic infections</li> <li>Daratumumab, isatuximab, and elotuzumab may be detected on SPEP and immunofixation assays as IgG-kappa</li> <li>Daratumumab and isatuximab can interfere with cross-matching and red blood cell antibody screening</li> <li>Elotuzumab-induced hepatotoxicity</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="2">Alkylating agents</td> </tr> <tr> <td class="indent1"> <ul> <li>Melphalan</li> <li>Cyclophosphamide</li> </ul> </td> <td> <ul> <li>GI toxicity and immune suppression with all doses</li> <li>Mucositis and alopecia with intermediate- or high-dose therapy</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="2">Other drugs</td> </tr> <tr> <td class="indent1"> <ul> <li>Bendamustine</li> </ul> </td> <td> <ul> <li>Infusion reactions, irritant with vesicant-like properties, GI toxicity, bone marrow suppression, increased serum bilirubin</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Doxorubicin</li> </ul> </td> <td> <ul> <li>Cardiomyopathy, vesicant, secondary malignancy, myelosuppression, alopecia</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Liposomal doxorubicin</li> </ul> </td> <td> <ul> <li>Cardiomyopathy, infusion reactions, hand-foot syndrome, GI toxicity, secondary malignancy, myelosuppression</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Corticosteroids (eg, dexamethasone, prednisone)</li> </ul> </td> <td> <ul> <li>GI toxicity, hyperglycemia, immune suppression, insomnia, altered mood, fluid retention</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Venetoclax</li> </ul> </td> <td> <ul> <li>Limited off-label use in t(11;14) myeloma</li> </ul> </td> </tr> <tr> <td class="indent1"> <ul> <li>Selinexor</li> </ul> </td> <td> <ul> <li>Hyponatremia, GI toxicity, neurologic toxicity</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="2">CAR-T cell therapy</td> </tr> <tr> <td class="indent1"> <ul> <li>Idecabtagene vicleucel</li> <li>Ciltacabtagene autoleucel</li> </ul> </td> <td> <ul> <li>REMS program; cytokine release syndrome, neurologic toxicity, hypersensitivity reactions, serious infections, prolonged cytopenias, prolonged hypogammaglobulinemia, hemophagocytic lymphohistiocytosis/macrophage activation syndrome, effects on ability to drive and use machines, and second malignancies</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="2">Bispecific antibodies</td> </tr> <tr> <td class="indent1"> <ul> <li>Teclistamab (targets BCMA and CD3)</li> <li>Elranatamab (targets BCMA and CD3)</li> <li>Talquetamab (targets GPRC5D and CD3)</li> </ul> </td> <td> <ul> <li>REMS program; cytokine release syndrome, neurologic toxicity, hypersensitivity reactions, serious infections, hepatotoxicity</li> <li>Additional toxicities with talquetamab include oral toxicity, weight loss, skin toxicity, and nail toxicity</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>BCMA: B cell maturation antigen; CAR: chimeric antigen receptor; GI: gastrointestinal; GPRC5D: G protein-coupled receptor, class C, group 5, member D; IgG: immunoglobulin G; REMS: risk evaluation and mitigation strategy; SLAMF7: signaling lymphocyte activation molecule 7; SPEP: serum protein electrophoresis.</p>
* Daratumumab and isatuximab are anti-CD38 monoclonal antibodies. Elotuzumab is an anti-SLAMF7 monoclonal antibody.</div><div id="graphicVersion">Graphic 121137 Version 15.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
